FDA panel calls for more research of amalgam risks

Labeling for dental amalgam should more clearly inform dental practitioners and their patients of the potential risks posed by the mercury it contains, an expert panel advised the U.S. Food and Drug Administration (FDA) at a two-day meeting in Gaithersburg, MD, this week.
And the FDA should do its own risk assessment and meta-analysis of scientific literature to gain an authoritative grasp of what is knowable about the dangers that mercury restorations may pose, particularly for sensitive subgroups such as pregnant women, their fetuses, young children, and medically vulnerable patients.

Continue Reading